長春高新(000661.SZ)子公司就聯合活疫苗獨家專有技術許可與俄羅斯醫藥公司簽署許可協議
格隆匯8月25日丨長春高新(000661.SZ)公佈重大合同公告，2019年8月15日，子公司百克生物與俄羅斯福特(FORT)國家生物醫藥公司在俄羅斯梁贊共同簽署了《專有技術相互許可協議》。
雙方約定在協議期限內，FORT為百克生物提供在中國境內使用的一種預防麻疹、腮腺炎、風疹的聯合活疫苗的獨家專有技術許可，百克生物為FORT提供在俄羅斯聯邦境內使用的一種預防水痘的減毒活疫苗。
在這種情況下，接收方有權生產許可產品(特別是在必要時使用專用設備、部件和原料)，使用許可產品，以及銷售這些產品。交付方不得在接收方的領土內，單獨使用這些權利，也不得將其交付給任何第三方。
公告顯示，《許可協議》的主要內容包括：1.1FORT將向百克生物提供“基於雞胚成纖維細胞和MRC-5細胞系生產麻疹、腮腺炎和風疹減毒聯合活疫苗的工藝”，包括：技術現狀的説明，即疫苗生產流程圖、工藝流程簡要説明和工藝流程的控制點列表；根據專有技術説明向百克生物提供病毒種子庫；提供基於雞胚成纖維細胞的疫苗成分上游過程的描述；FORT代表前往百克生物的生產現場，以接受或提供有關專有技術的諮詢。
1.2百克生物將向FORT公司提供“基於MRC-5細胞系生產水痘減毒活疫苗的工藝”，包括：“基於MRC-5細胞系生產水痘減毒活疫苗工藝”的病毒培養過程説明和上游工藝技術流程圖；涵蓋下游過程的專有技術階段的描述；百克生物代表前往FORT的生產現場或FORT指示的另一實驗室或生產車間接受或提供有關專有技術的諮詢支持。
據悉，該協議有效期為20年，自簽署之日起生效。公司表示，本次百克生物與FORT簽署專有技術相互許可協議，符合百克生物在生物疫苗領域的戰略佈局要求，有利於擴展公司疫苗的產品線和國際化佈局，項目的實施將對公司未來業務發展及經營業績提升產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
